摘要
目的探讨HBV-DNA、HBV PreS1 Ag和HBeAg3指标在提示乙型肝炎病毒复制、病情转归以及疗效观察等方面的作用。方法采用荧光定量PCR法检测HBV-DNA,以<5.0×102拷贝/mL为阴性。采用ELISA法检测"乙肝两对半"和HBV PreS1 Ag。结果151例乙肝病人中有58例HBeAg阳性标本,HBV-DNA与HBeAg、HBV PreS1 Ag阳性符合率分别为96.6%、87.9%。71例接受抗病毒治疗和80例未接受抗病毒治疗病人HBV-DNA与HBV PreS1 Ag阳性一致率分别为84.5%和46.6%,差异有统计学意义(χ2=20.944,P<0.01)。结论HBeAg阳性仍是现阶段乙型肝炎病毒复制监测的理想指标,HBV PreS1 Ag可作为HBV感染及既往或现症病毒复制的支持性指标,但不适于作为抗病毒治疗监测指标。
Objective To evaluate the values of using HBV-DNA, HBV PreS1 Ag and HBeAg index in the assessment of HBV replication and patient recovery. Method HBV-DNA was detected using fluorescence quantitative PCR. Sample with less than 5×10^2 copies/mL was considered as HBV negative. Five serological markers of hepatitis B and HBV-Pre S1 Ag were determined with ELISA. Result 58 out of 151 HBV cases were found to be HBeAg （＋）, in which the positive concordance rate of HBV-DNA （＋）/HBeAg （＋） and HBV-DNA （＋）/HBV-Pre S1 Ag （＋） was 96.6% and 87.9%, respectively. The percentage of coincidence rate of HBV-DNA and HBV PreS1 Ag in the 71 patients receiving antiviral treatment and the 80 non-treatment control subjects was 84.5% and 46.6% （X2= 20.944, P〈0.01）, respectively. Conclusion HBeAg is an appropriate indicator in the monitoring of HBV replication. Although HBV-Pre S1 Ag can be considered as an additional index of HBV infection or replication, this antigen is not suitable in the evaluation of the efficacy of HBV antiviral treatment.
出处
《热带医学杂志》
CAS
2008年第8期816-818,共3页
Journal of Tropical Medicine
